4-苄基-2-(氯甲基)吗啉 | 40987-25-5

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-苄基-2-(氯甲基)吗啉
• 中文别名: 2-(氯甲基)-4-苄基吗啉；4-苄基-2-氯甲基吗啡啉；N-苄基-2-氯甲基吗啉
• 英文名称: N-benzyl-2-chloromethylmorpholine
• 英文别名: 4-benzyl-2-(chloromethyl)morpholine；2-chloromethyl-4-(phenylmethyl)morpholine
• CAS: 40987-25-5
• 化学式: C₁₂H₁₆ClNO
• mdl: MFCD02681886
• 分子量: 225.718
• InChiKey: GVWRZZNYCOTWNN-UHFFFAOYSA-N

物化性质

• 熔点：
  46 °C
• 沸点：
  120-122°C 1mm
• 密度：
  1.132±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  C
• 危险类别码：
  R34
• 海关编码：
  2934999090
• 安全说明：
  S26,S36/37/39,S45
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险品运输编号：
  1759
• 危险性描述：
  H314
• 储存条件：
  室温且干燥

SDS

Name:	4-Benzyl-2-(chloromethyl)morpholine 97% Material Safety Data Sheet
Synonym:
CAS:	40987-25-5

Section 1 - Chemical Product MSDS Name:4-Benzyl-2-(chloromethyl)morpholine 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
40987-25-5	4-Benzyl-2-(chloromethyl)morpholine	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 40987-25-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: characteristic odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 120 - 122 deg C @1mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H16ClNO
Molecular Weight: 226

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Bases, oxidizing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 40987-25-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Benzyl-2-(chloromethyl)morpholine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, N.O.S.*
Hazard Class: 8
UN Number: 1759
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 40987-25-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 40987-25-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 40987-25-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-苄基-2-(氯甲基)吗啉 在 palladium on activated charcoal 盐酸 、 18-冠醚-6 、 potassium tert-butylate 、 氢气 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 维洛沙秦
  参考文献：
  名称：

  作为多巴胺D4受体配体的新系列吗啉和1,4-恶唑烷衍生物：合成和3D-QSAR模型。

  摘要：

  自多巴胺D（4）受体亚型的鉴定和关于其可能参与精神分裂症的推测以来，选择性D（4）配体的开发已投入大量工作。这些选择性配体可能是没有锥体束外副作用的有效抗精神病药。这项工作描述了对多巴胺D（4）受体具有选择性的新系列的2,4-二取代的吗啉和2,4-二取代的1,4-恶唑酮的合成。进行了使用GRID / GOLPE方法的3D-QSAR分析，目的是更好地了解化学结构与生物活性之间的关系。通过查看系数图，我们可以确定对于亲和力至关重要的区域位于两个苯环系统（对氯苄基）周围，和属于吗啉或1，4-氧杂庚烷体系的脂族胺。另外，吗啉或1，4-氧杂庚烷环的大小对于亲和力似乎很重要。

  DOI：

  10.1021/jm031111m
• 作为产物：
  描述：

  N-苄基乙醇胺 在 硫酸 作用下， 反应 4.0h， 生成 4-苄基-2-(氯甲基)吗啉
  参考文献：
  名称：

  NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS

  摘要：

  本发明涉及从嘧啶衍生的新化合物，以及制备该化合物的方法，获得的新中间体，将其用作药物的用途，含有该化合物的药物组合物，以及将其作为AKT抑制剂的治疗用途。

  公开号：

  US20130274253A1

文献信息

• [EN] INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS<br/>[FR] COMPOSÉS D'INDAZOLE EN TANT QU'AGONISTES DE RÉCEPTEUR DE 5-HT4
  申请人：SUVEN LIFE SCIENCES LTD

  公开号：WO2015092804A1

  公开（公告）日：2015-06-25

  The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxytryptamine 4 (5-HT4) receptor agonists

  本发明涉及一种新型吲唑化合物，其化学式为（I），其中R1为烷基或环烷基；（化学式II），包括其立体异构体和药学上可接受的盐。本发明还涉及制备这种化合物的方法和包含这种化合物的药物组合物。本发明的化合物在治疗与5-羟色胺4（5-HT4）受体激动剂相关的各种疾病中是有用的。
• Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides
  作者：Shiro Kato、Toshiya Morie、Katsuhiko Hino、Tatsuya Kon、Shunsuke Naruto、Naoyuki Yoshida、Tadahiko Karasawa、Junichi Matsumoto

  DOI：10.1021/jm00167a020

  日期：1990.5

  With the purpose of obtaining more potent and selective gastric prokinetic than metoclopramide (1), a new series of N-[(2-morpholinyl)alkyl]benzamides (17-52) were synthesized and their gastric prokinetic activity was evaluated by determining effects on the gastric emptying of phenol red semisolid meal and of resin pellets solid meal in rats and mice. The morpholinyl moiety was newly designed after

  为了获得比甲氧氯普胺（1）更有效和选择性的胃动力，合成了一系列新的N-[（2-吗啉基）烷基]苯甲酰胺（17-52），并通过测定对胃泌素的作用来评估其胃动力。大鼠和小鼠胃中酚红半固体粉和树脂颗粒固体粉的胃排空。考虑到西沙必利（2）的侧链结构后，新设计了吗啉基部分，并与甲氧氯普胺和西沙必利的4-氨基-5-氯-2-甲氧基苯甲酰基偶联时产生了所需的活性。苯甲酰基的取代基的改性显着影响了活性。特别是，
• Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists
  申请人：Bissantz Caterina

  公开号：US20070027173A1

  公开（公告）日：2007-02-01

  The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R 1 , R 2 and R 3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.

  本发明涉及作为V1a受体拮抗剂的吲哚-3-基-甲酰基-螺环-哌啶衍生物，其由公式I表示：其中，螺环-哌啶头基A以及残基R1、R2和R3如本文所述定义。本发明进一步涉及含有此类化合物的药物组合物，制备化合物和药物组合物的方法，以及它们在治疗痛经、高血压、慢性心力衰竭、血管升压素不适当分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁障碍中的用途。
• Pyrimidine derivatives
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：US05736550A1

  公开（公告）日：1998-04-07

  Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula ##STR1## wherein X is O or NR.sup.5, Y is O, S or NR.sup.5 wherein R.sup.5 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like; R.sup.1 and R.sup.2 may be the same or different and each is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like; R.sup.3 is CN, or COOR.sup.6 wherein R.sup.6 is a C.sub.1 -C.sub.6 alkyl group, a C.sub.3 -C.sub.6 cycloalkyl group, an aryl group or the like; R.sup.4 is --SR.sup.7 or --NR.sup.8 R.sup.9 wherein R.sup.7 is a C.sub.1 -C.sub.6 alkyl group; R.sup.8 is a C.sub.1 -C.sub.6 alkyl group or the like; R.sup.9 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like, or R.sup.8 and R.sup.9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) ##STR2## wherein R.sup.10 represents a C.sub.1 -C.sub.6 alkyl group or the like or a pharmacologically acceptable salt thereof. The above-mentioned compounds are useful as a gastrointestinal prokinetic agent used for the therapy of digestive tract diseases.

  嘧啶衍生物可用作胃肠促动力药物，其化学式表示为##STR1##其中X为O或NR.sup.5，Y为O、S或NR.sup.5，其中R.sup.5为氢原子、C.sub.1 -C.sub.6烷基或类似物；R.sup.1和R.sup.2可以相同也可以不同，每个都是氢原子、C.sub.1 -C.sub.6烷基或类似物；R.sup.3为CN，或COOR.sup.6，其中R.sup.6为C.sub.1 -C.sub.6烷基、C.sub.3 -C.sub.6环烷基、芳基或类似物；R.sup.4为--SR.sup.7或--NR.sup.8 R.sup.9，其中R.sup.7为C.sub.1 -C.sub.6烷基；R.sup.8为C.sub.1 -C.sub.6烷基或类似物；R.sup.9为氢原子、C.sub.1 -C.sub.6烷基或类似物，或R.sup.8和R.sup.9可以与它们连接的氮原子一起表示为化学式(X)的N-取代哌嗪环，其中R.sup.10代表C.sub.1 -C.sub.6烷基或类似物，或其药理学上可接受的盐。上述化合物可用作治疗消化道疾病的胃肠促动力药物。
• Fast and Efficient¹⁸F-Labeling by [¹⁸F]Fluorophenylazocarboxylic Esters
  作者：Stefanie K. Fehler、Simone Maschauer、Sarah B. Höfling、Amelie L. Bartuschat、Nuska Tschammer、Harald Hübner、Peter Gmeiner、Olaf Prante、Markus R. Heinrich

  DOI：10.1002/chem.201303409

  日期：2014.1.7

  Introduction of [18F]fluoride ion into the aromatic core of phenylazocarboxylic esters was achieved in only 30 seconds, with radiochemical yields of up to 95 % (85(±10) %). For labeling purposes, the resulting 18F‐substituted azoester can be further converted in radical‐arylation reactions to give biaryls, or in substitutions at its carbonyl unit to produce azocarboxamides.

  仅在30秒内即可将[ 18 F]氟离子引入到苯偶氮羧酸酯的芳族核中，放射化学产率高达95％（85（±10）％）。出于标记目的，可以将所得的18 F-取代的偶氮酯进一步在自由基芳构化反应中转化为联芳基，或在其羰基单元上进行取代以生成偶氮羧酰胺。